EN DE
Watch Jiangxi Rimag Group Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jiangxi Rimag Group Co Ltd (2522) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Jiangxi Rimag Group Co Ltd stock HK$0.57, price HK$4.24, that is 86.6% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

JR Jiangxi Rimag Group Co Ltd logo Thin data Nov 8, 2026

Jiangxi Rimag Group Co Ltd

2522 · HK
Very expensive, weak quality

Our calculation puts a fair price 87% below what the stock costs today.

Low debt
Mixed Growth (revenue 3y +3.6 %/yr in CNY)
Loss over the last twelve months · -2.9% net margin (TTM) · fiscal year 2025 0.4%
Fair value HK$0.5700 · Strongly overvalued
Quality 35/100
Negative free cash flow over the last twelve months
Trails peers (4/12)
Narrow moat 17/100 · thin data
Thin data
Watch Jiangxi Rimag Group Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$70.80 HK$4.10 Fair Value HK$0.5700 Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

29‑month range HK$4.10 – HK$70.80 · fair‑value band HK$0.5400 – HK$0.6000 · the HK$4.24 price screens above the HK$0.5700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Jiangxi Rimag Group Co in your weekly email

Every Wednesday you see whether Jiangxi Rimag Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internationally. It operates through Imaging Center Services, Imaging Solution Services, and Digital-Intelligent Services segments.

Show moreShow less

The company offers imaging examination and diagnostic imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures to hospitals and other medical institutions, health management companies, individual patients, and other healthcare customers; medical imaging operational management services; imaging equipment and software solutions; imaging capability improvement services; imaging empowerment solutions, such as equipment selection and configuration, quality control, remote consultation, medical staff training, clinical imaging capability analysis, and repair services.

It also provides Rimag Cloud services, including cloud storage and cloud film modules, remote diagnosis and consultation for complex cases, remote hosting services, imaging AI integration platform, refined operation management modules, cloud radiology information system (RIS) modules, and quality control modules; data processing and analysis solutions; and remote and AI diagnosis services.

In addition, the company engages in the operation and management of a medical imaging cloud platform that provides diversified imaging services; operation of a research and development center; technical support; sale of medical devices and consumables; clinic services; maintenance and installation of medical equipment; technology development of medical imaging cloud platforms; and medical imaging industry chain services.

Jiangxi Rimag Group Co., Ltd. was incorporated in 2014 and is headquartered in Beijing, China.

Stock analysis

Jiangxi Rimag Group Co Ltd (2522) currently trades at HK$4.24, while our model-based Fair Value estimate is HK$0.5700, 87% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of HK$2.01 per share, and 2 of the 24 models we run sit above the HK$4.24 price.

Bear case: the Growth Earnings group reads lowest at HK$0.2200, and 22 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.5400 (bear) to HK$0.6000 (bull), the price of HK$4.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jiangxi Rimag Group Co Ltd reported revenue of 873M CNY in FY2025 versus 592M CNY in FY2021, a compound +10.2%/yr. Reported net income was 3.7M CNY in FY2025.

Key figures

Market cap HK$2.1B (≈ $263M) Micro · P/S ratio 2.24 · Net margin 0.4% · Return on equity −3.0% · Return on assets (EBIT) −1.6% (5-year average) · Operating margin −1.6% · Revenue (TTM) 919M CNY · Revenue growth (YoY) +9.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).

What moves the price

The share trades about 75% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −87%, 2522 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (HK$0.1200 to HK$28.33). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$0.5400 Fair Value HK$0.5700 Bull HK$0.6000
Price HK$4.24 · Downside -86.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.8200 HK$1.05 HK$1.35 78
Growth DCF HK$0.8200 HK$1.02 HK$1.27 76
Owner Earnings HK$0.6200 HK$0.7600 HK$0.9300 74
All 24 models by family
DCF Models
FCF DCF HK$0.8200 HK$1.05 HK$1.35 78
Owner Earnings HK$0.6200 HK$0.7600 HK$0.9300 74
5Y Revenue Exit HK$0.7200 HK$0.9200 HK$1.17 70
5Y EBITDA Exit HK$1.48 HK$2.41 HK$3.54 71
5Y P/E Exit HK$0.6600 HK$0.7900 HK$0.9300 68
10Y Revenue Exit HK$0.7500 HK$0.9300 HK$1.17 64
10Y EBITDA Exit HK$1.17 HK$1.81 HK$2.74 64
10Y P/E Exit HK$0.7300 HK$0.8500 HK$1.01 62
Earnings-Based
Graham-Dodd HK$0.0900 HK$0.3400 HK$0.4600 61
Lynch FV HK$0.0800 HK$0.1200 HK$0.1600 58
PEG = 1.0 HK$0.0800 HK$0.1200 HK$0.1600 54
EPV HK$0.5400 HK$0.5700 HK$0.5900 73
Multiples
P/E Multiple HK$0.2100 HK$0.2800 HK$0.3500 63
P/S Multiple HK$0.1600 HK$0.2200 HK$0.2700 57
P/B Multiple HK$21.25 HK$28.33 HK$35.41 55
EV/EBIT HK$0.4500 HK$0.6000 HK$0.7500 65
EV/EBITDA HK$1.86 HK$2.48 HK$3.10 67
EV/Revenue HK$0.3200 HK$0.4600 HK$0.6000 53
Asset-Based
NCAV (Graham) HK$3.79 HK$5.74 HK$7.17 54
Growth DCF
Growth DCF HK$0.8200 HK$1.02 HK$1.27 76
Rev-Margin DCF HK$0.7200 HK$0.9200 HK$1.17 70
Economic Profit
Residual Income HK$3.12 HK$3.44 HK$3.98 68
ROIC Compounder HK$0.5400 HK$0.5700 HK$0.5900 68
Growth Earnings
Growth-Adj P/E HK$0.1500 HK$0.2200 HK$0.2900 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 53
Do the profits arrive as real cash?
Financial strength 65
Debt, balance sheet and risk of trouble
Investment 30
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 17
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−5.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.4%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−50% → 6%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +14.5% a year for the price.

2522 screens overvalued: fair value 87% below the price. Compare with HCA Healthcare, Inc →

Compare Jiangxi Rimag Group Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −86.6% · Bottom 25%
Profitability
Return on assets 0.1% · Below median
Net margin (12 months) −2.9% · Bottom 25%
Operating margin (12 months) −1.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 9.8% · Above median
Balance sheet
Debt / equity 0.08× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.88× · Cheapest 25%
P/S (12 months) 1.91× · Pricier than median
Price / free cash flow (fiscal year) 30.4× · Priciest 25%
EV/EBITDA 8.9× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)49 · sector 33
PAST (return on equity)0 · sector 31
HEALTH (low debt)96 · sector 90
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.74 $46.55 +105% vs 2522
Aier Eye Hospital Group 300015 ¥8.85 ¥10.88 +23% vs 2522
DaVita Inc DVA $179.28 $218.90 +22% vs 2522
HCA Healthcare, Inc HCA $504.42 $547.34 +9% vs 2522
Tenet Healthcare Corporation THC $290.27 $279.20 −4% vs 2522
The Ensign Group ENSG $185.09 $140.09 −24% vs 2522
Encompass Health Corporation EHC $142.51 $94.81 −33% vs 2522
Fresenius SE FRE €53.47 €34.77 −35% vs 2522
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,550 ₹5,234 −39% vs 2522
Dr. Sulaiman Al Habib Medical Services Group 4013 214.70 SAR 109.45 SAR −49% vs 2522

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jiangxi Rimag Group Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jiangxi Rimag Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2522

Frequently asked questions

Is Jiangxi Rimag Group Co Ltd (2522) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$0.5700 versus a price of HK$4.24, about 87% lower (overvalued).
What is the fair value of 2522?
Our model-based fair value for Jiangxi Rimag Group Co Ltd is HK$0.5700 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$4.24.
What is the quality score of 2522?
Jiangxi Rimag Group Co Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangxi Rimag Group Co Ltd (2522)?
Our model-based price target is the fair value of HK$0.5700 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario HK$0.5400, optimistic scenario HK$0.6000. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangxi Rimag Group Co Ltd stock forecast for 2026?
Our models put fair value at HK$0.5700, about 87% lower versus a price of HK$4.24 (overvalued). Cautious scenario HK$0.5400, optimistic scenario HK$0.6000. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangxi Rimag Group Co Ltd (2522)?
Jiangxi Rimag Group Co Ltd reported trailing-twelve-month revenue of about 919M CNY (latest available figure, as of Nov 8, 2026).
What growth is priced into Jiangxi Rimag Group Co Ltd (2522)?
For today's price to be fair in a discounted-cash-flow model, Jiangxi Rimag Group Co Ltd would have to grow free cash flow by +16.4 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +10.2 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 2522 use?
Our models discount Jiangxi Rimag Group Co Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jiangxi Rimag Group Co Ltd that is +16.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Jiangxi Rimag Group Co Ltd (2522) delivered so far?
Over the past 4 years revenue at Jiangxi Rimag Group Co Ltd grew +10.2 % a year. The price currently implies free-cash-flow growth of +16.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jiangxi Rimag Group Co Ltd (2522) growing?
The median revenue growth in the sector is +1.6 % a year. That is the yardstick for the growth priced into Jiangxi Rimag Group Co Ltd (+16.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jiangxi Rimag Group Co Ltd (2522)?
The free-cash-flow yield on the price is 4.11 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Jiangxi Rimag Group Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jiangxi Rimag Group Co Ltd (2522)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangxi Rimag Group Co Ltd it is HK$0.5700 per share (as of Nov 8, 2026), against a price of HK$4.24. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Jiangxi Rimag Group Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 2522 trades above its calculated fair value: price HK$4.24, fair value HK$0.5700, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2522?
No. The price is what the market pays today (HK$4.24); the fair value is what the company's own numbers justify (HK$0.5700). For Jiangxi Rimag Group Co Ltd the two are HK$3.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangxi Rimag Group Co Ltd worth?
The market values Jiangxi Rimag Group Co Ltd at about HK$2.1B (market capitalisation, as of Nov 8, 2026). Per share that is HK$4.24; our models calculate a fair value of HK$0.5700 per share.
What do the bullish and bearish scenarios say about 2522?
Our models span a range for Jiangxi Rimag Group Co Ltd: cautious scenario HK$0.5400, base HK$0.5700, optimistic HK$0.6000 per share (as of Nov 8, 2026, price HK$4.24). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangxi Rimag Group Co Ltd (2522)?
Balance-sheet figures for Jiangxi Rimag Group Co Ltd (as of Nov 8, 2026): return on equity −3.0%, debt of 0.08 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 2522 from its 52-week high?
Jiangxi Rimag Group Co Ltd trades at HK$4.24, about 75% below its 52-week high of HK$17.24 and 3% above the low of HK$4.10 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5700 is for.
Which stocks are comparable to Jiangxi Rimag Group Co Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangxi Rimag Group Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price HK$4.24, calculated fair value HK$0.5700 (−87%), Quality Score 35/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2522 calculated?
We run Jiangxi Rimag Group Co Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.5700 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Jiangxi Rimag Group Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangxi Rimag Group Co Ltd (2522)?
The closing price on Nov 10, 2026 was HK$4.24. Our model-based fair value is HK$0.5700, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangxi Rimag Group Co Ltd right now?
The price sits above even our optimistic bull case (HK$0.6000). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (HK$0.5400 to HK$0.6000), unusually little disagreement for a valuation.

Key figures of Jiangxi Rimag Group Co Ltd

How large is the market capitalisation of Jiangxi Rimag Group Co Ltd (2522)?
The market capitalisation of Jiangxi Rimag Group Co Ltd is HK$2.1B (≈ $263M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangxi Rimag Group Co Ltd (2522)?
The price-to-sales ratio of Jiangxi Rimag Group Co Ltd is 2.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Jiangxi Rimag Group Co Ltd (2522)?
The net margin of Jiangxi Rimag Group Co Ltd is 0.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangxi Rimag Group Co Ltd (2522)?
The return on equity (ROE) of Jiangxi Rimag Group Co Ltd is −3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangxi Rimag Group Co Ltd (2522)?
On an EBIT basis the return on assets of Jiangxi Rimag Group Co Ltd is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangxi Rimag Group Co Ltd (2522)?
The operating margin of Jiangxi Rimag Group Co Ltd is −1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangxi Rimag Group Co Ltd (2522)?
Revenue at Jiangxi Rimag Group Co Ltd is growing +9.8% versus a year earlier (3y avg +3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangxi Rimag Group Co Ltd (2522)?
Earnings per share at Jiangxi Rimag Group Co Ltd are growing +318% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Jiangxi Rimag Group Co Ltd (2522) hold?
Jiangxi Rimag Group Co Ltd holds more cash than debt, 1.3M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Jiangxi Rimag Group Co Ltd in the live analysis

One click puts Jiangxi Rimag Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.